EMA Committee Recommends Approval of Rasonque for Metastatic Pancreatic Cancer

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorization for Rasonque (daraxonrasib). This drug is intended for adults with metastatic pancreatic adenocarcinoma who have received at least one prior treatment. This recommendation follows a phased review, a new process designed to accelerate the assessment of high-priority medicines addressing unmet medical needs.